本周医药届的28个小故事

[Tlexander]

1. **What Trump's CMS can and can't change with the second round of drug price negotiations**
*Explains the limitations and potential impact of the Trump administration's drug price negotiations on healthcare costs.*

2. **FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit**
*The FDA has approved a new breast cancer treatment from AstraZeneca and Daiichi Sankyo, even though it doesn't show a survival benefit.*

3. **JPM's M&A Monday frenzy; Ozempic selected for IRA negotiations; Pfizer says it's back on track; and more**
*Summarizes recent mergers and acquisitions, updates on Ozempic drug negotiations, and Pfizer's recovery plan.*

4. **Sionna and Odyssey end JPM week with IPO filings**
*Two biotech companies, Sionna and Odyssey, filed for Initial Public Offerings (IPOs) to raise funds.*

5. **Sage sues Biogen days after $469M buyout offer**
*Sage Therapeutics is suing Biogen shortly after Biogen offered to buy Sage for $469 million.*

6. **Another US biotech emerges with drug candidate from China-based Keymed**
*A new biotech company in the US has a drug candidate that originated from the Chinese company Keymed.*

7. **WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeutics**
*WuXi AppTec sold a unit that tests medical devices, and Notch Therapeutics is laying off workers.*

8. **Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted**
*Novo claims success in a Phase 3 trial for a high-dose version of its weight-loss drug Wegovy, though sales might not increase significantly.*

9. **Ozempic makes list for next round of Medicare drug price negotiations**
*Ozempic, a popular weight-loss drug, will be included in upcoming Medicare drug price negotiations.*

10. **AstraZeneca wins BTK race to market in first-line mantle cell lymphoma**
*AstraZeneca has won the race to bring a drug to market for mantle cell lymphoma, a rare cancer.*

11. **After three-month delay, Amgen’s Lumakras clinches FDA green light in colorectal cancer**
*Amgen’s cancer drug Lumakras has been approved by the FDA for use in colorectal cancer after a delay.*

12. **Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s**
*Roche's cardiometabolic expert cautions against focusing too much on weight loss drugs like GLP-1s.*

13. **Teva says it has a 'unique position' in latest IRA challenge**
*Teva Pharmaceuticals claims it has a special advantage in a legal challenge related to drug pricing.*

14. **Shionogi lands $375M from HHS to develop preventive drug for Covid-19**
*Shionogi, a pharmaceutical company, has secured $375 million from the U.S. government to develop a preventive Covid-19 drug.*

15. **Vaccine patch startup collects an additional $16M to Series A**
*A startup developing vaccine patches has raised $16 million in funding to advance its technology.*

16. **Umoja’s $100M Series C will advance its bid for more convenient cell therapies**
*Umoja, a biotech company, has raised $100 million to develop easier-to-use cell therapies.*

17. **Normunity nabs $75M Series B to advance T cell engager and launch first trial**
*Normunity has raised $75 million to move forward with a T cell engager therapy and launch its first clinical trial.*

18. **Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo**
*Eli Lilly is acquiring cancer biotech Scorpion, a company co-founded by the same person behind Loxo.*

19. **A mixed year for deals and dollars left biotech execs hungry for a better 2025**
*2024 was a year of mixed results in biotech deals, and executives are hoping for a better year in 2025.*

20. **Regenxbio sells Hunter syndrome license with FDA filing underway**
*Regenxbio has sold the license for its treatment of Hunter syndrome, and the FDA filing for approval is in progress.*

21. **Australia's BioCina and NovaCina join forces to make one CDMO**
*Two Australian companies, BioCina and NovaCina, have merged to form one contract development and manufacturing organization (CDMO).*

22. **Denmark’s new manufacturing learning center; Telix buys facility, assets and tech from ImaginAb**
*Denmark has opened a new center for manufacturing training, and Telix Pharmaceuticals has purchased a facility from ImaginAb.*

23. **Eli Lilly misses 2024 revenue expectations, stock dips 7%**
*Eli Lilly's revenue for 2024 fell short of expectations, causing its stock to drop by 7%.*

24. **Charles River disappoints investors with damp outlook for 2025**
*Charles River Laboratories gave a disappointing forecast for 2025, causing concern among investors.*

25. **Aragen gets $100M from private equity firm to expand manufacturing footprint**
*Aragen has secured $100 million in funding from a private equity firm to expand its manufacturing operations.*

26. **AstraZeneca, CRISPR tools supplier ink gene editing enzyme licensing deal**
*AstraZeneca has signed a licensing deal with a supplier of CRISPR gene-editing enzymes.*

27. **Samsung Bio extends ADC partnership; Veeda rebrands as CDMO**
*Samsung Bio has extended its partnership for antibody-drug conjugates (ADC), and Veeda has rebranded as a contract development and manufacturing organization (CDMO).*

28. **Synaffix adds Boehringer and Mitsubishi Tanabe as ADC licensing partners**
*Synaffix has added Boehringer Ingelheim and Mitsubishi Tanabe as partners for licensing antibody-drug conjugates (ADCs).*